SUZHOU, China and ROCKVILLE, Md., Dec. 2, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase IIa clinical study of the company’s novel MDM2-p53 Read More ›

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced it has entered into an agreement with the University of Michigan, through which the company may obtain the exclusive global rights to a MDM2 protein degrader Read More ›

SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical study of the company’s novel Bcl-2 inhibitor APG-2575, as a single agent or in combinations for the treatment of patients Read More ›

SUZHOU, China and ROCKVILLE, Md., Nov. 9, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from two pivotal Phase II studies of the company’s novel BCR-ABL inhibitor, HQP1351 (olverembatinib), have been accepted for oral presentation at the 62nd American Read More ›

SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020  — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase Ib/II study of Ascentage Pharma’s novel MDM2-p53 Read More ›

SUZHOU, China and ROCKVILLE, MD., Oct. 21, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Guangzhou Healthquest Pharma Co., Ltd, Read More ›

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted two Orphan Drug Designations (ODDs) to two of the company’s apoptosis-targeting assets: the MDM2-p53 inhibitor, Read More ›

SUZHOU, China and ROCKVILLE, MD., Sept. 14, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-115, a novel MDM2-p53 inhibitor being developed by the company, an Read More ›

SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for Read More ›

SUZHOU, China and ROCKVILLE, MD., August 27, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that preclinical study results of the company’s novel inhibitor of apoptosis proteins (IAP) antagonist APG-1387 in the treatment of CHB infection Read More ›